Effect of Topiramate on Weight Gain in Patients Receiving Atypical Antipsychotic Agents

@article{Mahmood2013EffectOT,
  title={Effect of Topiramate on Weight Gain in Patients Receiving Atypical Antipsychotic Agents},
  author={Shamail Mahmood and Ian Booker and Judy Huang and Craig I. Coleman},
  journal={Journal of Clinical Psychopharmacology},
  year={2013},
  volume={33},
  pages={90–94}
}
Background Clinical Antipsychotic Trials of Intervention Effectiveness showed that atypical antipsychotics (AAPs) were associated with significant weight gain and glucose intolerance. A few trials have shown topiramate to reduce weight gain in patients receiving AAPs, although this benefit has not been present in all trials. Objective This study aimed to determine topiramate therapy’s impact on weight gain in patients receiving AAPs. Data Source A systematic literature search of MEDLINE (1948… Expand
Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials
TLDR
Topiramate was significantly superior to control group in mitigating weight gain and psychopathology in antipsychotic-treated patients with schizophrenia and need further investigations in larger definitive studies using methodological rigor and thorough assessments. Expand
Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: a randomized-controlled trial
TLDR
Topiramate, similar to metformin in reducing obesity as previously reported, also significantly reduced body weight, BMI, and waist–hip ratio in patients with antipsychotic-induced obesity and demonstrated well tolerance in psychiatric patients. Expand
Topiramate Adjunctive Therapy for Olanzapine Induced Weight Gain in Patients with Schizophrenia
  • Sanjib Pandit
  • Medicine
  • Journal of Karnali Academy of Health Sciences
  • 2019
TLDR
No consistent findings are available to clearly explain the underlying psychopathology of disease spectrum in schizophrenia, though recent finding from a clinical trial carried out in healthy male volunteers have suggested that the low baseline TSH profile predicts Olanzapine related weight gain and also interestingly relief by Topiramate adjuvant therapy. Expand
Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis
  • Yewei Wang, Dandan Wang, +6 authors Chen Zhang
  • Medicine
  • Journal of psychopharmacology
  • 2021
TLDR
Considering both efficacy and tolerability, evidence from this NMA indicates zonisamide, metformin, GLP-1RAs, and nizatidine in adults should be the first-line treatment for alleviating AAPs-induced weight gain or elevated BMI. Expand
Antiepileptic drugs influences on body weight in people with epilepsy
  • S. Hamed
  • Medicine
  • Expert review of clinical pharmacology
  • 2015
TLDR
The possible contribution of peripheral and central hormones/neuropeptides (as leptin, insulin, adiponectin, neuropeptide-Y, ghrelin and galanin) and pathways that influence energy balance in the pathogenesis of weight changes with AEDs are discussed. Expand
Antipsychotic Medication-Associated Weight Gain: Development of an Evidence-Based Management Algorithm and Practice Guideline for Primary Care Providers
TLDR
This practice inquiry project investigated the problem of antipsychotic medication-associated weight gain by applying the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) methodology to develop a preliminary evidence-based practice guideline and algorithm for use by primary care providers. Expand
BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
TLDR
These guidelines review issues surrounding monitoring of physical health risk factors and make recommendations about an appropriate approach to interventions for people experiencing weight gain when taking antipsychotic medications. Expand
Therapies for obesity and medication-associated weight gain.
  • R. Howland
  • Medicine
  • Journal of psychosocial nursing and mental health services
  • 2013
TLDR
Behavioral lifestyle interventions to promote weight loss are effective and should be implemented along with or instead of drug therapies or surgery. Expand
Topiramate: antipsychotic-induced weight gain.
TLDR
This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. Expand
Topiramate: Antipsychotic-Induced Weight Gain
This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for informationExpand
...
1
2
3
...

References

SHOWING 1-10 OF 27 REFERENCES
Topiramate as an Adjuvant Treatment With Atypical Antipsychotics in Schizophrenic Patients Experiencing Weight Gain
TLDR
Results suggest that a higher dose of topiramate is efficacious as an adjuvant treatment of patients with schizophrenia experiencing excess weight gain, and further clinical research is required to establish guidelines for the use ofTopiramate as an antiobesity agent in schizophrenic patients. Expand
Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial
TLDR
Topiramate could prevent olanzapine induced weight gain and adverse metabolic effects in patients with schizophrenia and results in a greater clinical improvement when used with olanZapine in schizophrenia. Expand
Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial
TLDR
Topiramate can be an effective medication in controlling schizophrenic symptoms, considering its effect on negative symptoms and controlling antipsychotic-associated weight gain. Expand
Influence of Topiramate on Olanzapine-Related Adiposity in Women: A Random, Double-Blind, Placebo-Controlled Study
TLDR
Topiramate appears to be a safe and effective agent in the treatment of weight gain that occurred during olanzapine treatment and significantly positive changes in health-related quality of life, the patient's actual state of health, and psychologic impairments were observed. Expand
Efficacy and safety of topiramate on weight loss: a meta‐analysis of randomized controlled trials
TLDR
In conclusion, topiramate might be a useful adjunctive therapeutic tool in the treatment of obesity as long as proper warnings about side effects are considered. Expand
Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study
TLDR
The results obtained indicate that topiramate appeared to be scarcely effective for reducing clinical symptomatology in schizophrenic patients who have had an incomplete clinical response to clozapine. Expand
The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis.
TLDR
This analysis suggests that using metformin in patients treated with AAPs may reduce metabolic risks, and additional randomized controlled trials are needed to support consideration of this intervention in clinical practice. Expand
Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension.
TLDR
In conclusion, topiramate produced clinically relevant effects in reducing body weight and BP, with generally mild to moderate adverse effects. Expand
Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
TLDR
Glutamate antagonist topiramate may be an effective adjuvant treatment in reducing general psychopathologic symptoms in patients with schizophrenia resistant to treatment with second-generation antipsychotics. Expand
A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders.
TLDR
Adjunctive sibutramine and topiramate may have comparable weight loss effects in overweight or obese bipolar patients with psychotropic-associated weight gain, but are each associated with similarly high discontinuation rates. Expand
...
1
2
3
...